The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Abstract
The induction of anti-influenza cytotoxic T lymphocytes (CTL) in vivo by immunizing mice with liposomes containing messenger RNA (mRNA) encoding the influenza virus nucleoprotein (NP) is described. NP mRNA, obtained by in vitro transcription, was encapsulated into simple cholesterol/phosphatidylcholine/phosphatidylserine liposomes by the detergent removal technique. The dependence of the route of mRNA-liposomes delivery on CTL induction was studied. The CTL induced were identical to those obtained in vivo with infectious virus in terms of specificity, lysing both peptide-sensitized and virus-infected targets. Furthermore, with the same mRNA-liposome preparation, virus-specific CTL responses could be also elicited in mice of three different haplotypes each of them known to present a distinct NP peptide in an MHC-restricted fashion. The relevance of these results in the context of vaccine development is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hence, mRNA vaccines have been formulated with synthetic delivery vehicles such as liposomes (16) and cationic polymers (17) to increase potency.”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [16]
In the citing paper
“It was not until 1993 that mRNA was used as a vaccine for the first time to elicit a specific immune response against the encoded pathogenic antigen in a preclinical setting using lipid-based delivery.22”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [22]
In the citing paper
“The first mRNA vaccine was made of liposomes and mRNA encoding an influenza virus nucleoprotein184.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [184]
In the citing paper
“This vaccine, designed in 1993, was able to induce virus-specific cytotoxic T cell responses in mice184.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [184]
In the citing paper
“Lipid nanoparticle–mRNA vaccines are also being investigated as influenza vaccines29,41,156,157,159,184,189–191, with some formulations in clinical trials (Table 1).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [184]
In the citing paper
“As pioneers, Martinon et al. showed that liposomes containing mRNA encoding the influenza virus nucleoprotein elicited virus-specific cytotoxic T lymphocytes (CTLs) [3].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [3]
In the citing paper
“encapsulation of RNA in lipid carriers 72 , and their utility in vaccination 73 , was demonstrated.”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [73]
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Cationic liposome-mediated RNA transfection.
Malone, R. W., Felgner, P. L., & Verma, I. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6077 · Cited by 911
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
Deres, K., Schild, H., Wiesmüller, K., Jung, G., & Rammensee, H. (1989) · Nature · doi:10.1038/342561a0 · Cited by 632
Morrison, L. A., Lukacher, A. E., Braciale, V. L., Fan, D. P., & Braciale, T. J. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.163.4.903 · Cited by 507
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
Takahashi, H., Takeshfta, T., Morein, B., Putney, S. D., Germain, R. N., & Berzofsky, J. A. (1990) · Nature · doi:10.1038/344873a0 · Cited by 473
A molecular model of MHC class-I-restricted antigen processing
Monaco, J. J. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90122-n · Cited by 433
Kast, W. M., Roux, L., Curren, J., Blom, H., Voordouw, A. C., Meloen, R. H., Kolakofsky, D., & Melief, C. J. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2283 · Cited by 326
Peptide-induced antiviral protection by cytotoxic T cells.
Schulz, M., Zinkernagel, R. M., & Hengartner, H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.991 · Cited by 239
Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide.
Aichele, P., Hengartner, H., Zinkernagel, R. M., & Schulz, M. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.5.1815 · Cited by 198
Townsend, A., & Skehel, J. J. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.160.2.552 · Cited by 182
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–472 of 472
Adjuvants, the Elephant in the Room for RNA Vaccines
D’haese, S., den Roover, S., & Aerts, J. L. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_12 · Cited by 1
Nanotechnology-Driven Delivery Systems in Inoculation Therapies
Pereira, G. C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2716-7_3 · Cited by 1
Applications of Spray-Dried Vaccines
Arpagaus, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-24323-3_6 · Cited by 2
Nanotechnology in vaccines and personalized medicine
Azevedo, M. S. P., & Patri, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00043-5 · Cited by 1
Du, P., & Wang, Q. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1201 · Cited by 1
The Potential of mRNA Vaccines to Fight Against Viruses
Wang, X. (2024) · Viral Immunology · doi:10.1089/vim.2024.0047 · Cited by 2
Lipid-Based Systems for Regenerative Medicine
Patel, P., Bagada, A. A., Garala, K., Singh, S. K., & Prajapati, B. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-87744-5_5 · Cited by 1
Entwicklung von RNA‐basierten Impfstoffen
Roos, T. (2015) · Biologie in unserer Zeit · doi:10.1002/biuz.201510555 · Cited by 1
Nucleic acid-based vaccines of COVID-19 and their delivery systems
Yang, H., Zhang, M., Weng, Y., Cao, Y., & Huang, Y. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0051 · Cited by 1
Gill, K., Minall, L., & Nassif, A. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814357-5.00007-6 · Cited by 1
Lacheiner, K. (2010) · UpSpace Institutional Repository (University of Pretoria) · Cited by 1
médecine/sciences en 2022, une passion pour la recherche…
Teillaud, J. (2022) · médecine/sciences · doi:10.1051/medsci/2022001 · Cited by 1
(2023) · Nature Materials · doi:10.1038/s41563-023-01770-3 · Cited by 1
Editorial: Post COVID-19: the nucleoside-modified messenger RNA (modRNA) platform
Roncati, L., & Huo, Q. T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1324610 · Cited by 1
DNA-Based Immunization: Prospects For a Hepatitis B Vaccine
Davis, H. L., & Whalen, R. G. (1995) · Springer eBooks · doi:10.1007/978-1-4613-0357-2_16 · Cited by 1
Pascolo, S. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse028
Immune Responses with Direct Gene Transfer: DNA Vaccines and Implications for Gene Therapy
Davis, H. L. (1996) · Springer eBooks · doi:10.1007/978-1-4615-6405-8_3
Multifunctional bioreducible nanoparticles for gene therapy
Li, J. (2012) · Human Biology
Plasmid DNA and Messenger RNA for Therapy
Pascolo, S. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse320
Genetic Modulation of Antigen Presentation
Hedley, M. L. (1996) · Springer eBooks · doi:10.1007/978-1-4684-6462-7_17
Biotechnologie 2.0 — Impfstoffe und Medikamente auf Basis von mRNA
Theß, A., & Grund, S. E. (2014) · BIOspektrum · doi:10.1007/s12268-014-0483-5
Enhancing Dendritic Cell Migration to Drive Antitumor Responses
Batich, K. A. (2017)
Exploring the potential of novel multivalent DNA-based vaccines
Fissolo, N. (2004) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-549
Immunotherapy of High-Grade Gliomas: Preclinical In Vivo Experiments in Animal Models
Batich, K. A., Choi, B. D., & Mitchell, D. A. (2012) · Neuromethods · doi:10.1007/7657_2012_38
Cancer Vaccines: Some Basic Considerations
Rammensee, H., Singh‐Jasuja, H., Emmerich, N., & Pascolo, S. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369420-1.00050-0
Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy
Madkour, L. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819777-6.00021-4
Historical Development Process of mRNA Vaccines and SARS-CoV-2 Pandemic
GÜNEŞ, N., & Karabulut, Ş. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.14
Dános, V., & Szabó, C. (2021) · Belügyi Szemle · doi:10.38146/bsz.2021.2.8
Possibilities and principles of vaccination against COVID-19
Křupka, M., Kosztyu, P., Racanský, M., Schovánek, J., Sloupenská, K., Strojil, J., & Raška, M. (2021) · Praktické lékárenství · doi:10.36290/lek.2021.001
The development of science is uninterrupted
Dános, V., & Szabó, C. (2021) · Belügyi Szemle · doi:10.38146/bsz.spec.2021.1.9
Together at all times: committed to quality
Santo, J. P. D., & Bakočević, N. (2021) · European Journal of Immunology · doi:10.1002/eji.202170096
La révolution des vaccins à ARN
Dolgin, E. (2021) · Pour la Science · doi:10.3917/pls.522.0022
The mRNA Technology in Cancer Immunotherapy
Persano, F., Leporatti, S., Persano, S., Guevara, M. L., & Gigli, G. (2022) · Current Nanomaterials · doi:10.2174/2405461507666220131110055
(1994) · Journal of Microencapsulation · doi:10.3109/02652049409040442
mRNA-based nanovaccines as newer treatment modalities in cancer
Dubey, A. K., Das, S. S., Hosseinpour, M., Verma, P. R. P., Singh, S. K., & Singh, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823686-4.00006-9
Messenger RNA Therapeutics: Start of a New Era in Medicine
Jain, S., George, A. J., Sharma, V., Singh, G., & Gupta, V. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_3
Propriété industrielle et recherche fondamentale dans la genèse du vaccin ARNm contre la COVID-19
Migus, A. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.06.014
Asaleh, A., Zhou, J., & Rahmanian, N. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29223.aas
Farrell, R. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90221-2.00041-2
Messenger RNA Nanovaccine in Cancer Immunotherapy
Li, M., & Zhang, H. (2022) · Springer eBooks · doi:10.1007/978-3-031-17831-3_9
Promising Studies in the 1990s
Lemonnier, J., & Lemonnier, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-39300-6_6
The Use of mRNA—The Initial Technical Obstacles
Lemonnier, J., & Lemonnier, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-39300-6_7
YuanChao, X. U. E. (2023) · Scientia Sinica Vitae · doi:10.1360/ssv-2023-0236
Les perspectives de l’ARN messager en oncologie
Spano, J. (2023) · Actualités Pharmaceutiques · doi:10.1016/s0515-3700(23)00477-9
The pivotal role of uridine modifications in the development of mRNA technology
Rzymski, P. (2023) · Journal of Medical Science · doi:10.20883/medical.e938
Комісаренко, С. В., & Романюк, С. И. (2023) · Visnik Nacional noi academii nauk Ukrai ni · doi:10.15407/visn2023.12.003
Сергеевна, Ш. Г., Reshetnikov, V. V., Авдиенко, В. Г., Shevyrev, D., Yeremeev, V., & Ivanov, R. A. (2023) · Bulletin of Russian State Medical University · doi:10.24075/vrgmu.2023.054 · Cited by 4
Vaccination ARN messager (ARNm), modèle de transition de la biologie fondamentale à la médecine
Sansonetti, P. J. (2024) · Comptes Rendus Biologies · doi:10.5802/crbiol.129
RNA therapeutics for disorders of excretory system
Vu, T.-D., Nguyen, M. A., Jurgoński, A., & Chu, D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.011
Shou, Y., & Lou, J. (2024) · Journal of Applied Analysis & Computation · doi:10.11948/20230365
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4801-1
TÜRKİYE’DE AŞI KARARSIZLIĞI VE BİLİM İLETİŞİMİ: TIBBİ VE SOSYOLOJİK BİR YAKLAŞIM
Övet, C. (2024) · Sosyal ve Beşeri Bilimler Dergisi · doi:10.55978/sobiadsbd.1331672
Introduction to mRNA and mRNA-based therapeutics
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00001-7
Nanomedicine’s Role in the COVID-19 Vaccine Development and Optimization
Kumar, J., Malhotra, J., Yadav, A. S., & Bhati, A. S. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_3
mRNA vaccines: The new frontier
Yan, Z., Yang, M. J., Tian, E., & Lai, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00021-8
Saw, P. E., & Song, E. (2025) · Springer eBooks · doi:10.1007/978-981-96-3041-7_26
Historical Overview of RNA Therapeutics
Saw, P. E., & Song, E. (2025) · Springer eBooks · doi:10.1007/978-981-96-3041-7_1
RNA in the Central Dogma: mRNA
Saw, P. E., & Song, E. (2025) · Springer eBooks · doi:10.1007/978-981-96-3041-7_3
1985-2025, les Quarante Glorieuses de l’immunologie
Sibéril, S., & Teillaud, J. (2025) · médecine/sciences · doi:10.1051/medsci/2025128
Inhibitory Effect of Lipid Nanoparticle–Encapsulated AtRDR1 on Tumor CellsPreprint
Huang, R. S., Li, W., Bi, B., Liu, X., Yang, Y., Ma, C., Liu, Y., Wang, Q., Hu, H., & Yan, Q. (2026) · Research Square · doi:10.21203/rs.3.rs-9111057/v1
DNA vaccination amplifiers HLA-DR cross-restricted public TCR clonotypes shared with HIV controllers
Mukhopadhyay, M. (2017) · theses.fr (ABES) · doi:10.70675/a42f696ez8360z43b6z95a3z984bca393809
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Analytical Characterization and Stability Assessment of RNA-Based Vaccines
Alasmari, H., Alghannam, S. F., Almoammar, H., Alrabiah, D. K., Harthy, S. A., Alyamani, E. J., Alyahya, S. A., Alkhrayef, M. N., Fallatah, M., Al‐Khaldi, S., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070790
Kim, B. K., Park, J.-H., Choi, W.-S., Oh, S., An, S. H., Lee, G. C., Chokkakula, S., Kim, C.-U., Jeong, J. H., Min, S. C., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.047
Nanomaterials in Vaccine Development
Mir, M., Wani, B. G., Gupta, P. K., & Chauhan, D. (2026) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-032-29006-9_6
Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics
Athanasopoulou, K., Daneva, G. N., Michalopoulou, V.-I., Stamelou, M.-L., Tsiakanikas, P., & Adamopoulos, P. G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080809
Target, silence, replace: a review on RNA-based drugs in modern medicine
Mundlia, P., Singh, S. P., Pothal, P., Thakur, T., Kathuria, R., Maurya, S., Sharma, A., Goel, H., Pandey, A., Ranawat, P., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1879681
mRNA Vaccines as Novel Immunotherapeutic Approaches in Gastrointestinal Cancers
Ghidini, M., Novazzi, F., Denaro, N., Petrillo, A., Ratti, M., Salati, M., Malvaso, R., Marco, L. D., Parisi, A., & Hahne, J. C. (2026) · Cells · doi:10.3390/cells15181673
Hybrid lipid-nanogels: nanolipogels for mRNA delivery
Oudkerk-Sodia, E., Xu, R., Chu, R., Dabas, R., Patri, S., Tidd, C., Blagojevic, L., Woscholski, R., & Kamaly, N. (2026) · RSC Advances · doi:10.1039/d6ra07548g
mRNA-based therapies: From molecular discovery to clinical revolution
de Oliveira, A. P., Sodré, F. M. C., Louzada-Neto, O., Zylberman, M. C., da Silva, J. R., Ferreira, L. C. D. S., & Menck, C. F. M. (2026) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2026-0026
Metadata
- Authors
- Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P.
- Affiliations
- Inserm (FR)
- Institut Cochin (FR)
- Corresponding author
- Meulien, Pierre
- ORCID
- Martinon, Frédéric
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1993-07
- Volume
- 23
- Issue
- 7
- Pages
- 1719-1722
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2083958143
- Cited by
- 473
- References
- 28
- Citations by year
- 2026: 18 · 2025: 42 · 2024: 51 · 2023: 59 · 2022: 58 · 2021: 64 · 2020: 18 · 2019: 10 · 2018: 12 · 2017: 8 · 2016: 12 · 2015: 13 · 2014: 12 · 2013: 9 · 2012: 10
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- cytotoxic T lymphocytes, influenza virus, nucleocapsid protein, mRNA vaccines, MHC restriction, peptide presentation, vaccine development, in vitro transcription
- MeSH terms
- Animals, Antigens, Viral, Cytotoxicity, Immunologic, Immunity, Cellular, Liposomes, Mice, Inbred Strains, Nucleoproteins, Influenza A virus, RNA, Messenger, T-Lymphocytes, Cytotoxic, Vaccines, Synthetic, Viral Core Proteins, Viral Vaccines, Nucleocapsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
